Drug Profile
Research programme: plasma-derived biopharmaceutical therapeutics - NantPharma/Liminal BioSciences
Alternative Names: Intravenous immune globulin - NantPharma/Liminal BioSciencesLatest Information Update: 14 Oct 2019
Price :
$50
*
At a glance
- Originator NantPharma; ProMetic Life Sciences
- Developer Liminal BioSciences; NantPharma
- Class Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunodeficiency disorders
Most Recent Events
- 03 Oct 2019 Prometic Life Sciences is now called Liminal BioSciences
- 28 Jul 2018 No recent reports of development identified for preclinical development in Immunodeficiency-disorders in USA (IV)
- 02 Apr 2014 Preclinical trials in Undefined indication in USA (unspecified route)